Related Experiment Video
Updated: Sep 20, 2025

Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Tannaz Jamialahamdi1, Elaheh Mirhadi2, Wael Almahmeed3
1Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Background:
A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap.
Methods:
Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery.
Results:
A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: - 15.730, 95% CI: - 22.140, - 9.320, p < 0.001). This effect remained robust in sensitivity analysis.
Conclusion:
The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

